natgillin/translations-raw huggingface dataset:
Breast enlargement**** Breast pain**** Galactorrhoea**** Erectile dysfunction**** Amenorrhoea**** Dysmenorrhoea****
povećanje dojki**** bol u dojkama**** galaktoreja**** erektilna disfunkcija**** amenoreja**** dismenoreja
Breast feeding
Dojenje
Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.
Kod žena koje uzimaju lijek Latuda, dojenje se preporučuje samo ako potencijalna korist liječenja nadmašuje potencijalni rizik za dijete.
Breast inflammation
upala dojke
Breast inflammation
upala dojki
breast inflammation*
upala dojki
Breast inflammation/mastitis
artralgija
Breast inflammation/mastitis
upala dojke/mastitis
Breast mass
kvržica u dojci
Breast milk should be discarded within the first 24 hours after thrombolytic therapy.
U prva 24 sata nakon trombolitičkog liječenja majčino mlijeko treba baciti.
breast overdevelopment in men adrenal insufficiency
prekomjerni razvoj dojki u muškarca zatajenje nadbubrežne žlijezde
breast pain
bol u dojkama,
breast pain, breast discomfort, enlargement of the glands in your breasts, breast enlargement, discharge from the breasts
bol dojki, nelagoda u dojkama, povećanje žlijezdi u dojkama, povećanje dojki, iscjedak iz dojki
Breast pain, breast tenderness, swollen breasts
Bolovi i osjetljivost u dojkama, oticanje dojki
Breast pain.
bol u dojkama
Breast problems such as pain, enlargement or lumps in the breast
problemi s dojkama poput bolnosti, povećanje dojki ili kvržice na dojkama
breast swelling in boys
oticanje dojki kod dečki
Breast tenderness
osjetljivost dojki
Breast tenderness Hypertrophy breast
osjetljivost dojki hipertrofija dojki
Breast tenderness Menstruation irregular Vaginal discharge Libido decreased
dismenoreja, osjetljivost dojki, neredovite menstruacije, vaginalni iscjedak, smanjeni libido,
Breast –feeding
Dojenje
Breast, cervical or liver cancer
rak dojke, grlića maternice ili jetre
Breast- feeding must therefore be avoided.
Dojenje stoga treba izbjegavati.
Breast-feeding
hipotenzija, flebitis
Breast-feeding
krvarenje u retini
Breast-feeding
Metadon:
Breast-feeding (see section 4.6)
Dojenje (vidjeti odjeljak 4.6)
Breast-feeding is not recommended during treatment with Arixtra.
Tijekom liječenja lijekom Arixtra ne preporuča se dojenje.
Breast-feeding is not recommended during treatment with Arzerra and for 12 months after the last time you were treated with Arzerra.
Dojenje se ne preporučuje tijekom terapije lijekom Arzerra te tijekom 12 mjeseci nakon zadnjeg puta kada ste primili lijek Arzerra.
Breast-feeding is not recommended during treatment with Leganto.
Dojenje se ne preporučuje tijekom liječenja Legantom.
Breast-feeding is not recommended during treatment with Neupro.
Dojenje se ne preporučuje tijekom liječenja Neuprom.
Breast-feeding is not recommended during treatment with STAYVEER.
Dojenje se ne preporučuje tijekom liječenja STAYVEEROM.
Breast-feeding is not recommended during treatment with Tasigna.
Dojenje se ne preporučuje tijekom liječenja Tasignom.
Breast-feeding is not recommended during treatment with Tracleer.
Dojenje se ne preporučuje tijekom liječenja Tracleerom.
Breast-feeding is not recommended for 24 hours following removal of IONSYS.
Dojenje se ne preporučuje do 24 sata nakon uklanjanja sustava IONSYS.
Breast-feeding mothers
Majke koje doje
Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest caffeine- containing foods and beverages or medicinal products containing caffeine (see section 4.6), since caffeine is excreted into breast milk (see section 5.2).
Majke koje doje svoju novorođenčad liječenu kofeincitratom ne smiju konzumirati hranu i pića koja sadrže kofein ili lijekove koji sadrže kofein (vidjeti dio 4.6), jer se kofein izlučuje u majčino mlijeko (vidjeti dio 5.2).
Breast-feeding mothers of newborn infants treated with caffeine citrate should not ingest caffeine- containing foods, beverages or medicinal products containing caffeine.
Majke koje doje novorođenčad liječenu kofeincitratom, ne bi smjele konzumirati hranu, pića i lijekove koji sadrže kofein.
Breast-feeding mothers should not breast- feed for 24 hours after treatment with this medicine.
Majke koje doje ne bi smjele dojiti 24 sata nakon uzimanja ovog lijeka.
Breast-feeding mothers should not take Kaletra unless specifically directed by the doctor.
Dojilje ne smiju uzimati lijek Kaletra, osim ako im to izričito ne kaže liječnik.
Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
Dojilje ne smiju uzimati lopinavir/ritonavir, osim ako im to izričito ne kaže liječnik.
Breast-feeding must be discontinued during pemetrexed therapy (see section 4.3).
Dojenje se tijekom liječenja pemetreksedom mora prekinuti (vidjeti dio 4.3).
Breast-feeding must be discontinued in women who are receiving therapy with Tyverb.
Dojenje se mora prekinuti kod žena koje se liječe lijekom Tyverb.
Breast-feeding must be stopped on initiation of treatment with VFEND.
atrofija vidnog živca, zamućenje rožnice
Breast-feeding must be stopped on initiation of treatment with Voriconazole Hospira.
Dojenje se mora prekinuti prije početka liječenja lijekom Vorikonazol Hospira.
Breast-feeding should be avoided if you are on Wilzin therapy.
Ukoliko ste na terapiji Wilzinom trebate izbjegavati dojenje.
Breast-feeding should be discontinued during and up to five months after treatment.
Dojenje treba prekinuti tijekom i do pet mjeseci nakon liječenja.
Breast-feeding should be discontinued during treatment with Akynzeo and for 1 month after the last dose.
Dojenje treba prekinuti tijekom liječenja Akynzeom i još 1mjesec nakon zadnje doze.
Breast-feeding should be discontinued during treatment with asfotase alfa.
Dojenje treba prekinuti za vrijeme liječenja asfotazom alfa.
Breast-feeding should be discontinued during treatment with Baraclude.
Dojenje treba prekinuti tijekom liječenja lijekom Baraclude .
Breast-feeding should be discontinued during treatment with pazopanib.
Treba prekinuti dojenje tijekom terapije pazopanibom.
Breast-feeding should be discontinued during treatment with Pixuvri.
Dojenje treba prekinuti za vrijeme liječenja Pixuvriom.
Breast-feeding should be discontinued during treatment with Portrazza and for at least 4 months after the last dose.
Dojenje treba prekinuti tijekom liječenja lijekom Portrazza i još najmanje 4 mjeseca nakon posljednje doze.
Breast-feeding should be discontinued during treatment with this medicine.
Dojenje se mora prekinuti za vrijeme liječenja ovim lijekom.
Breast-feeding should be discontinued for at least 24 hours after you receive Optimark.
Nakon primjene Optimarka, dojenje treba prekinuti na barem 24 sata.
Breast-feeding should be discontinued for at least 4 days after NexoBrid application.
Dojenje treba prekinuti tijekom najmanje 4 dana nakon primjene NexoBrida.
Breast-feeding should be discontinued while receiving treatment with capecitabine.
Dojenje se mora prekinuti dok traje liječenje kapecitabinom.
Breast-feeding should be interrupted for 12 hours after application of Ameluz.
Dojenje treba prekinuti 12 sati nakon primjene lijeka Ameluz.
Breast-feeding should be interrupted for 24 hours after treatment with this medicinal product.
Dojenje bi trebalo prekinuti tijekom 24 sata od primjene ovog lijeka.
Breast-feeding while taking INCRELEX is not recommended.
Dojenje se ne preporučuje tijekom uzimanja INCRELEXA.
Breast-feeding women (see section 4.6).
Dojilje (vidjeti dio 4.6.).
Breast-feeding women must, therefore, not receive teriflunomide.
Dojilje stoga ne smiju primati teriflunomid.
Breast-feeding women.
Dojilje.
Breast-feeding:
Dojenje
Breast-feeding:
Dojenje:
Breast-feeding: it is unknown whether bexarotene is excreted in human milk.
Dojenje: Nije poznato izlučuje li se beksaroten u majčino mlijeko u ljudi.
Breast-feeding: it is unknown whether entecavir is excreted in human milk.
Dojenje: nije poznato izlučuje li se entekavir u majčino mlijeko.
Breast-Feeding: Women taking Axura should not breast-feed.
Dojenje: žene koje uzimaju Axuru ne semiju dojiti.
Breast-Feeding: Women taking Axura should not breast-feed.
Dojenje: žene koje uzimaju Axuru ne smiju dojiti.
Breast-Feeding: Women taking Memantine Merz should not breast-feed.
Dojenje: žene koje uzimaju Memantine Merz ne semiju dojiti.
Breast-Feeding: Women taking Memantine Merz should not breast-feed.
Dojenje: žene koje uzimaju Memantine Merz ne smiju dojiti.
Breast-Feeding: Women taking Memantine Merz should not breast-feed.
Dojenje: žŽene koje uzimaju Memantine Merz ne semiju dojiti.
Breast-feeding¨
Dojenje
Breastfed infants, if the mother is treated with medicines contraindicated with propranolol
Dojene bebe, ako se majka liječi lijekovima kontraindiciranima s propranololom
Breastfeeding
Plodnost, trudnoća i dojenje
Breastfeeding (see section 4.6)
Dojenje (vidjeti dio 4.6)
Breastfeeding is not recommended during treatment with sodium oxybate.
Dojenje se ne preporučuje tijekom liječenja natrijevim oksibatom.
Breastfeeding is not recommended when you take Zalviso.
Dojenje nije preporučeno kada uzimate Zalviso.
Breastfeeding is not recommended while taking ISENTRESS.
Za vrijeme uzimanja lijeka ISENTRESS dojenje se ne preporučuje.
Breastfeeding mothers: see section 4.4 and section 4.5.
Majke koje doje: vidjeti dio 4.4 i dio 4.5.
Breastfeeding should be discontinued during treatment with ofatumumab and for 12 months following treatment.
Dojenje treba prekinuti tijekom terapije ofatumumabom i 12 mjeseci nakon terapije.
Breastfeeding women (see section 4.6)
Dojilje (vidjeti dio 4.6)
Breastfeeding women must not take this medicine.
Dojilje ne smiju uzimati ovaj lijek.
breasts
dojke
Breasts
Grudi
Breasts3
Dojke3
Breast­feeding
Dojenje
Breath bags:
Vrećice za izdahnuti zrak:
Breath odour
Zadah iz usta
Breath sample container
Spremnik za uzorak izdahnutog zraka
BREATH SAMPLE CONTAINERS: GLASS OR PLASTIC
SPREMNICI ZA UZORKE IZDAHNUTOG ZRAKA: STAKLENI ILI PLASTIČNI
Breathe in rapidly but steadily and as deeply as you can.
Kako biste udahnuli lijek duboko u dišne puteve:
Breathe in rapidly but steadily and as deeply as you can.
Udahnite brzo, ali postojano te što dublje možete.
Breathe in rapidly but steadily, as deeply as you can.
Kako biste udahnuli lijek duboko u dišne puteve:
Breathe in rapidly but steadily, as deeply as you can.
Kako biste udahnuli lijek duboko u dišne putove:
Breathe in rapidly but steadily, as deeply as you can.
Udahnite brzo ali postojano te što dublje možete.
Breathe normally (inhale and exhale) through the mouthpiece.
Dišite normalno (udišite i izdišite) kroz usnik.
Breathe out
Izdahnite
Breathe out slowly and gently.
Polako i nježno izdahnite.
Breathe out, and then breathe normally again.
Izdahnite, a zatim počnite ponovno disati.
breathing difficulties
otežano disanje
Breathing difficulties
otežano disanje povišeni jetreni enzimi
breathing difficulties
poteškoće pri disanju
Breathing difficulties
poteškoće s disanjem
Breathing difficulties
teškoće s disanjem
breathing difficulties (dyspnoea)
otežano disanje (dispneja)
Breathing difficulties (slow or shallow breathing)
teškoće s disanjem (sporo ili plitko disanje)
Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax.
tegobe s disanjem ili piskanje pri disanju koje se pogorša neposredno nakon uzimanja Aerivio Spiromaxa.
Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax.
tegobe s disanjem ili piskanje pri disanju koje se pogorša neposredno nakon uzimanja Airexar Spiromaxa.
breathing difficulties sometimes associated with cough
teškoće pri disanju, ponekad povezane s kašljem
breathing difficulties, cough, chest pain
otežano disanje, kašalj, bol u prsima
breathing difficulties, hoarseness, difficulty in speaking skin redness, nettle rash (urticaria) or itching.
poteškoće pri disanju, promuklost, teškoće pri govoru crvenilo kože, koprivnjača (urtikarija) ili svrbež.
breathing disorders
poremećaji disanja
breathing disorders, shortness of breath, inflammation of the lungs.
poremećaji disanja, nedostatak zraka, upala pluća
Breathing disorders: Interstitial pneumonia (inflammation of the lungs including fatal outcome), blood clots in the lung
Poremećaji dišnog sustava: intersticijska upala pluća (upala pluća uključujući smrtni ishod), krvni ugrušci u plućima
Breathing problems
Problemi s disanjem
Breathing problems (bronchopulmonary dysplasia),
Problemi s disanjem (bronhopulmonalna displazija),
breathing problems (including shortness of breath),
tegobe s disanjem (uključujući nedostatak zraka),
Breathing problems including persistent cough/or shortness of breath or fever.
Problemi pri disanju uključujući stalni kašalj/ili nedostatak zraka ili vrućicu.
breathing problems, asthma or chronic obstructive pulmonary disease poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome)
dišnih problema, astme ili kronične opstruktivne bolesti pluća slabe cirkulacije (bolesti perifernih krvnih žila kao što je Raynaudova bolest ili Raynaudov sindrom),
breathing problems, asthma or chronic obstructive pulmonary disease poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome)
poteškoće s disanjem, astmu ili kroničnu opstruktivnu plućnu bolest poremećaj krvotoka (kao što je Raynaudova bolest ili Raynaudov sindrom)
breathing problems, asthma or chronic obstructive pulmonary disease poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome)
tegobe sa disanjem, astmu ili kroničnu opstruktivnu plućnu bolest poremećaj krvotoka (kao što je Raynaudova bolest ili Raynaudov sindrom)
breathing problems, cough, dry throat, difficulty in swallowing,
tegobe s disanjem, kašalj, suho grlo, poteškoće s gutanjem,
Breathing problems: Kadcyla can cause serious breathing problems such as shortness of breath (either at rest or while performing any type of activity) and cough.
Probleme s disanjem: Kadcyla može izazvati ozbiljne probleme s disanjem poput nedostatka zraka (u mirovanju ili pri izvođenju bilo kakve vrste aktivnosti) i kašlja.
breathing trouble chest pain
otežano disanje bol u prsima
Breathlessness
nedostatak daha
breathlessness
nedostatak zraka
breathlessness
zaduha
Breathlessness (dyspnoea)
Nedostatak zraka (dispneja)
breathlessness (including breathlessness at night)
nedostatak zraka (uključujući nedostatak zraka tijekom noći)
breathlessness (including breathlessness at night),
nedostatak zraka (uključujući nedostatak zraka tijekom noći),
Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure)
Nedostatak zraka, otežano disanje u ležećem položaju, oticanje stopala ili nogu (znakovi zatajenja srca)
breathlessness, hiccups, nasal congestion, sore throat
nedostatak zraka, štucanje, začepljenost nosa, grlobolja
breathlessness.
nedostatak zraka.
Breda 4817 ZJ,
4817 ZJ Breda
Breelib is a small handheld, battery-powered, breath activated, vibrating mesh technology system.
Breelib je mali, ručni, atomizatorski sustav s baterijskom napajanjem s tehnologijom vibrirajuće mrežice koji se aktivira udahom.
Breelib nebuliser
Atomizator Breelib
Breelib nebuliser:
Breelib atomizator:
Bretaris Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Bretaris Genuair od 322 µg, prašak inhalata aklidinij (aklidinijev bromid)
Bretaris Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Bretaris Genuair 322 mikrograma, prašak inhalata aklidinij (aklidinijev bromid)
Bretaris Genuair contains lactose monohydrate
Bretaris Genuair sadrži laktozu hidrat
Bretaris Genuair is a white or almost white powder.
Bretaris Genuair je bijel ili gotovo bijeli prašak.
Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Bretaris Genuair je indiciran u terapiji održavanja bronhodilatacije za ublažavanje bronhoopstruktivnih simptoma, u odraslih bolesnika s kroničnom opstruktivnom bolesti pluća (KOPB).
Bretaris Genuair is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
Bretaris Genuair se koristi u terapiji održavanja bronhodilatacije kod kronične opstruktivne bolesti pluća, i ne treba ga koristiti za liječenje iznenadnog napadaja nedostatka zraka ili piskanja.
Bretaris Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, long-term lung disease characterised by breathing difficulties.
Bretaris Genuair se koristi za pomoć pri otvaranju dišnih puteva i ublažavanje simptoma KOPB-a, ozbiljne, dugotrajne plućne bolesti koju karakterizira otežano disanje.
Bretaris Genuair is not for use in children or adolescents below 18 years of age.
Bretaris Genuair nije namijenjen djeci i adolescentima mlađim od 18 godina.
Bretaris Genuair should be used with caution in patients with a myocardial infarction during the previous 6 months, unstable angina, newly diagnosed arrhythmia within the previous 3 months, or hospitalisation within the previous 12 months for heart failure functional classes III and IV as per the “New York Heart Association”.
Bretaris Genuair treba koristiti oprezno kod bolesnika s infarktom miokarda u prethodnih 6 mjeseci, nestabilnom anginom, novo dijagnosticiranom aritmijom u prethodna 3 mjeseca, ili hospitalizacijom u prethodnih 12 mjeseci zbog zatajenja srca klase III i IV, prema „New York Heart Association“ (NYHA) klasifikaciji.
Bretaris Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Bretaris Genuair se ne smije koristiti kod astme; nisu provedena klinička ispitivanja aklidinijeva bromida kod astme.
Bridgend Industrial Estate Bridgend, CF31 3RT United Kingdom
Bridgend Industrial Estate Bridgend, CF31 3RT Velika Britanija
Bridgend, CF31 3RT United Kingdom
Bridgend, CF31 3RT Velika Britanija
Bridging fibrosis
5% (2/37) (1%, 18%)b
Bridging fibrosis
Premoštavajuća fibroza
Bridion can be used during breast-feeding.
Bridion se može koristiti tijekom dojenja.
Bridion can make hormonal contraceptives - including the ‘Pill’, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone.
Bridion može umanjiti djelotvornost hormonskih kontraceptiva – uključujući kontracepcijske tablete, vaginalni prsten, implantate ili hormonski intrauterini uložak – jer smanjuje količinu hormona progestagena dobivenu iz kontraceptiva.
Bridion contains sodium
Bridion sadrži natrij
Bridion has no known influence on your ability to drive and use machines.
Nema poznatog utjecaja lijeka Bridion na sposobnost upravljanja vozilima i rada sa strojevima.
Bridion is a clear and colourless to slightly yellow solution for injection.
Bridion je bistra i bezbojna do blago žuta otopina za injekciju.
Bridion will be given to you by your anaesthetist.
Bridion će Vam dati anesteziolog.
Brief background on lenalidomide and its licensed indication
Kratku povijest lenalidomida i njegove odobrene indikacije.
Brief background on Odomzo, its licensed indication and posology
Kratki pregled osnovnih podataka o Odomzu, njegovu odobrenu indikaciju i doziranje
Brief background on pomalidomide and its licensed indication
osnovna saznanja o pomalidomidu i njegove odobrene indikacije
Brief background on Tasigna, its authorised indication and posology
Kratki pregled osnovnih informacija o Tasigni, odobrenoj indikaciji i doziranju
Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product.
Kratkotrajan dodir životinje s vodom jedan do dva puta između mjesečnih tretmana malo je vjerojatno da će značajno smanjiti učinkovitost proizvoda.
Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product.
Kratkotrajan doticaj životinje s vodom jednom ili dva puta između mjesečnog tretiranja, nije vjerojatno da će značajno smanjiti učinkovitost proizvoda.
Brief contact of the animal with water within the month following application is unlikely to reduce the efficacy of the product.
Kratak dodir životinje s vodom tijekom mjesec dana od primjene neće utjecati na učinkovitost proizvoda.
Brief information on preparation and administration instructions.
Sažete informacije o pripremi i informacije o primjeni.
Brief introduction of aripiprazole indication and the purpose of the tool
Kratak uvod u indikaciju za primjenu aripiprazola i namjenu knjižice
Brief introduction to aripiprazole indication and the purpose of the tool
Kratak uvod u indikaciju za primjenu aripiprazola i namjenu knjižice
Brief introduction to ipilimumab (indication and the purpose of this tool).
Kratke uvodne informacije o ipilimumabu (indikacija i namjena brošure).
Brief introduction to ipilimumab indication and the purpose of this tool.
Kratke uvodne informacije o indikaciji ipilimumaba i namjeni brošure
Brief introduction to RAS and its role in the panitumumab mechanism of action
Kratki uvod u RAS i njegovu ulogu u mehanizmu djelovanja panitumumaba
Brief introduction to the Vectibix indication and the purpose of this tool
Kratki uvod u indikacije za primjenu lijeka Vectibix i svrha ovog alata
Briefly press and release red button.
Nakratko pritisnite pa otpustite crveni gumb.
Bright red blood in vomit or stools
vijetlocrvenu krv u povraćanom sadržaju ili stolici,
bright/red blood in the stools bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
vijetla/crvena krv u stolici krvarenje nakon bilo koje operacije, uključujući nastanak modrica i oticanje, istjecanje krvi ili tekućine iz kirurške rane/reza (iscjedak iz rane) ili s mjesta injekcije
brightness,
krvarenje,
brightness,
osjećaj svjetline
Brilique 60 mg film-coated tablets ticagrelor
Brilique 60 mg filmom obložene tablete tikagrelor
Brilique 90 mg film-coated tablets ticagrelor
Brilique 90 mg filmom obložene tablete tikagrelor
Brilique affects cells called ‘platelets’ (also called thrombocytes).
Brilique djeluje na stanice koje se nazivaju krvnim pločicama (ili trombocitima).
Brilique contains ticagrelor, a member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is an oral, direct acting, selective and reversibly binding P2Y12 receptor antagonist that prevents ADP-mediated P2Y12 dependent platelet activation and aggregation.
Brilique sadrži tikagrelor, koji pripada kemijskoj skupini ciklopentiltriazolopirimidina (CPTP), peroralni je, direktno djelujući, selektivni antagonist P2Y12 receptora koji se reverzibilno veže i sprječava ADP-om posredovanu, o P2Y12 ovisnu aktivaciju i agregaciju trombocita.
Brilique does not affect tests of pulmonary function.
Brilique ne utječe na testove plućne funkcije.
Brilique is not recommended for children and adolescents under 18 years.
Brilique se ne preporučuje za djecu i adolescente u dobi ispod 18 godina.
Brilliant Blue (E133) Allura Red AC (E129) Titanium dioxide (E171) Sunset Yellow FCF (E110)
Brilliant Blue (E133) Allura Red AC (E129) Titanijev dioksid (E171) Sunset Yellow FCF (E110)
Brimica Genuair 340 micrograms /12 micrograms inhalation powder aclidinium/formoterol fumarate dihydrate
Brimica Genuair 340 mikrograma/12 mikrograma, prašak inhalata aklidinij/formoterolfumarat dihidrat
Brimica Genuair 340/12 mcg inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair 340/12 μg, prašak inhalata aklidinij/formoterolfumarat dihidrat
Brimica Genuair 340/12 micrograms inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair 340/12 mikrograma, prašak inhalata aklidinij/formoterolfumarat dihidrat
Brimica Genuair has been studied in 2 main studies involving over 3,400 patients with COPD, in which it was compared with aclidinium alone, formoterol alone and placebo (a dummy treatment).
Brimica Genuair ispitan je u 2 glavna ispitivanja koja su obuhvatila više od 3 400 bolesnika s KOPB- om, u kojima je ovaj lijek uspoređen s monoterapijom aklidinijem, monoterapijom formoterolom i placebom (liječenjem bez djelatne tvari).